The Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline drugs market research report outlays comprehensive information on the Ubiquitin Carboxyl Terminal Hydrolase 7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Oncology. It also reviews key players involved in Ubiquitin Carboxyl Terminal Hydrolase 7 targeted therapeutics development with respective active and dormant or discontinued products.

The Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline targets constitutes close to six molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.

Ubiquitin Carboxyl Terminal Hydrolase 7 overview

Ubiquitin Carboxyl Terminal Hydrolase 7 is an enzyme that in humans is encoded by a gene USP7. This is also known as ubiquitin carboxyl-terminal hydrolase 7 or herpesvirus-associated ubiquitin-specific protease (HAUSP). It belongs to the peptidase C19 family, which includes ubiquitinyl hydrolases. USP7 deubiquitinates target proteins such as p53 (a tumor suppressor protein) and WASH (essential for endosomal protein recycling), and regulates their activities by counteracting the opposing ubiquitin ligase activity of proteins such as HDM2 and TRIM27, involved in the respective process. Mutations in this gene have been implicated in a neurodevelopmental disorder.

For a complete picture of Ubiquitin Carboxyl Terminal Hydrolase 7’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.